# Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

> **NCT02698280** · PHASE2 · COMPLETED · sponsor: **Huashan Hospital** · enrollment: 23 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Nimustine

## Key facts

- **NCT ID:** NCT02698280
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-01
- **Final completion:** 2018-05
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02698280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02698280, "Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02698280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*